http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112921093-B
Outgoing Links
Predicate | Object |
---|---|
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-136 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-178 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-14 |
filingDate | 2021-03-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2022-06-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2022-06-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | CN-112921093-B |
titleOfInvention | Application of lnc-AGO2 functional expression inhibitor in preparation of medicine for treating breast cancer |
abstract | The invention discloses an application of a lnc-AGO2 functional expression inhibitor in preparation of a medicine for treating breast cancer, and belongs to the technical field of biological medicines. The lnc-AGO2 functional expression inhibitor is RNAi, shRNA lentivirus, sgRNA, ZFN, TALEN element or homologous recombination vector. According to the invention, the expression of lnc-AGO2 in breast cancer cells is obviously increased, the method can be used for detecting breast cancer, an in vitro lnc-AGO2 knockout breast cancer cell model and an in vivo lnc-AGO2 knockout breast cancer in-situ transplantation tumor model series experimental study are established, the research proves that lnc-AGO2 can obviously inhibit the proliferation capacity of the breast cancer cells and obviously promote the apoptosis of the breast cancer cells, and the knockout of lnc-AGO2 can be used for preventing or treating the breast cancer, so that an lnc-AGO2 functional expression inhibitor can be prepared for treating the breast cancer. |
priorityDate | 2021-03-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 198.